Clinical Trials Logo

Clinical Trial Summary

The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.


Clinical Trial Description

The purpose and goal of the Alpha-1 Research Registry (Registry, or group of patients) will be to obtain uniform, longitudinal (over the course of time), complete and accurate data that can be organized, and made available for the public to query. The collective number of Registry members enables investigators to enroll sufficient subjects to carry out their studies. The community benefits from having more research and potential therapies performed in their disease. Regular updates from patients will give objective data-points to measure the progression of disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04157049
Study type Observational [Patient Registry]
Source Alpha-1 Foundation
Contact Alison Keaveny, MBBS
Phone 1-877-228-7321
Email akeaveny@alpha1.org
Status Recruiting
Phase
Start date June 20, 2019
Completion date June 20, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2
Completed NCT00396006 - Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) Phase 4
Completed NCT04174118 - Study of DCR-A1AT in Healthy Adult Volunteers Phase 1
Completed NCT05579431 - A Phase 1, First-in-human Study of VX-634 Phase 1
Recruiting NCT05856331 - Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema Phase 2
Suspended NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02168686 - Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/Phase 2
Recruiting NCT04204252 - Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD Phase 3
Completed NCT00067756 - 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Phase 2
Not yet recruiting NCT06389877 - A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1/Phase 2
Completed NCT00295061 - Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 3
Completed NCT00001462 - Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals N/A
Active, not recruiting NCT05297812 - Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Completed NCT03114020 - Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT00460096 - Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Phase 2/Phase 3
Completed NCT00377416 - Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Early Phase 1
Terminated NCT00005098 - Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency N/A
Completed NCT03362242 - Study of ARO-AAT in Normal Adult Volunteers Phase 1